JP2022507697A5 - - Google Patents
Info
- Publication number
- JP2022507697A5 JP2022507697A5 JP2021527114A JP2021527114A JP2022507697A5 JP 2022507697 A5 JP2022507697 A5 JP 2022507697A5 JP 2021527114 A JP2021527114 A JP 2021527114A JP 2021527114 A JP2021527114 A JP 2021527114A JP 2022507697 A5 JP2022507697 A5 JP 2022507697A5
- Authority
- JP
- Japan
- Prior art keywords
- independently selected
- alkyl
- ring
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024230959A JP2025066719A (ja) | 2018-11-19 | 2024-12-26 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769327P | 2018-11-19 | 2018-11-19 | |
| US62/769,327 | 2018-11-19 | ||
| US201962861781P | 2019-06-14 | 2019-06-14 | |
| US62/861,781 | 2019-06-14 | ||
| PCT/US2019/062238 WO2020106736A1 (en) | 2018-11-19 | 2019-11-19 | Compounds and compositions for treating conditions associated with sting activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024230959A Division JP2025066719A (ja) | 2018-11-19 | 2024-12-26 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022507697A JP2022507697A (ja) | 2022-01-18 |
| JP2022507697A5 true JP2022507697A5 (enExample) | 2022-11-29 |
Family
ID=69005817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527114A Pending JP2022507697A (ja) | 2018-11-19 | 2019-11-19 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| JP2024230959A Pending JP2025066719A (ja) | 2018-11-19 | 2024-12-26 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024230959A Pending JP2025066719A (ja) | 2018-11-19 | 2024-12-26 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230047905A1 (enExample) |
| EP (1) | EP3883651A1 (enExample) |
| JP (2) | JP2022507697A (enExample) |
| CN (2) | CN119735540A (enExample) |
| MA (1) | MA55138A (enExample) |
| WO (1) | WO2020106736A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI873098B (zh) | 2018-07-03 | 2025-02-21 | 瑞士商諾華製藥公司 | 用於治療與sting活性相關之病症的化合物及組合物 |
| JP2022517797A (ja) * | 2019-01-17 | 2022-03-10 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| US20220227760A1 (en) * | 2019-05-29 | 2022-07-21 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| US20230106899A1 (en) | 2019-06-21 | 2023-04-06 | Ifm Due, Inc. | Methods of treating cancer |
| US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| EP4247790B1 (en) | 2020-11-23 | 2024-10-09 | Regor Pharmaceuticals, Inc. | Sting antagonists and uses thereof |
| JP2024504002A (ja) * | 2020-12-22 | 2024-01-30 | アイエフエム デュー インコーポレイテッド | がんを処置する方法 |
| JP2024500877A (ja) * | 2020-12-22 | 2024-01-10 | アイエフエム デュー インコーポレイテッド | がんを処置する方法 |
| US20240122903A1 (en) | 2020-12-22 | 2024-04-18 | Ifm Due Inc. | Methods of treating cancer |
| JP2024500874A (ja) | 2020-12-22 | 2024-01-10 | アイエフエム デュー インコーポレイテッド | がんを処置する方法 |
| JP2024502474A (ja) | 2021-01-08 | 2024-01-19 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物 |
| GB202110084D0 (en) * | 2021-07-13 | 2021-08-25 | Univ Oxford Innovation Ltd | Sulfur compounds and processes and intermediates useful in the preparation thereof |
| WO2023285788A1 (en) * | 2021-07-13 | 2023-01-19 | Oxford University Innovation Limited | Sulfur compounds and processes and intermediates useful in the preparation thereof |
| AU2022326463A1 (en) | 2021-08-10 | 2024-02-22 | Novartis Pharma Ag | Compounds and compositions for treating conditions associated with sting activity |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US7754755B2 (en) * | 2004-09-23 | 2010-07-13 | Bristol-Myers Squibb Company | Inhibitors of 15-lipoxygenase |
| EP1836188A1 (en) * | 2004-12-30 | 2007-09-26 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| WO2012075380A1 (en) | 2010-12-03 | 2012-06-07 | The Trustees Of The University Of Pennsylvania | Tip60 inhibitors |
| EP2996472B1 (en) * | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| AU2014340269B2 (en) | 2013-10-21 | 2018-06-21 | Drexel University | Use of STING agonists to treat chronic hepatitis B virus infection |
| CA3042317A1 (en) * | 2016-11-01 | 2018-05-11 | F.Hoffmann-La Roche Ag | Pyridazine derivatives as rorc modulators |
| ES2891326T3 (es) * | 2017-01-27 | 2022-01-27 | Janssen Biotech Inc | Dinucleótidos cíclicos como agonistas de la STING |
| WO2019076778A1 (en) * | 2017-10-16 | 2019-04-25 | Syngenta Participations Ag | HETEROCYCLIC DERIVATIVES HAVING PESTICIDAL ACTIVITY HAVING SUBSTITUENTS CONTAINING SULFUR AND SULFONIMIDAMIDES |
| CN112823151B (zh) * | 2018-07-03 | 2024-11-15 | 艾福姆德尤股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
-
2019
- 2019-11-19 EP EP19827876.4A patent/EP3883651A1/en not_active Withdrawn
- 2019-11-19 WO PCT/US2019/062238 patent/WO2020106736A1/en not_active Ceased
- 2019-11-19 CN CN202411912017.4A patent/CN119735540A/zh active Pending
- 2019-11-19 CN CN201980089438.2A patent/CN113382772B/zh active Active
- 2019-11-19 US US17/294,965 patent/US20230047905A1/en not_active Abandoned
- 2019-11-19 JP JP2021527114A patent/JP2022507697A/ja active Pending
- 2019-11-19 MA MA055138A patent/MA55138A/fr unknown
-
2024
- 2024-12-26 JP JP2024230959A patent/JP2025066719A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023509421A5 (enExample) | ||
| JP2022517797A5 (enExample) | ||
| JP2021529834A5 (enExample) | ||
| JP2021529833A5 (enExample) | ||
| JP6839772B2 (ja) | 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP6839761B2 (ja) | 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP7461741B2 (ja) | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン | |
| JP7046973B2 (ja) | 抗ｏｘ４０抗体およびその使用 | |
| KR102607101B1 (ko) | Cd47 항원 결합 유닛 및 그것의 사용 | |
| JP7000357B2 (ja) | 免疫調節剤としての複素環化合物 | |
| CN110087680B (zh) | 使用包含btk抑制剂的组合产品治疗癌症 | |
| TWI629483B (zh) | anti-TIM-3 antibody | |
| US10973915B2 (en) | Anti-PD-1 antibodies and uses thereof | |
| WO2017118321A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| KR102460736B1 (ko) | 화학적으로-로킹된 이중특이적 항체 | |
| WO2019089969A2 (en) | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen | |
| KR102380150B1 (ko) | Gitr 항체, 방법, 및 용도 | |
| JP2019513809A5 (enExample) | ||
| WO2019030377A1 (en) | CD96 BINDING AGENTS AS IMMUNOMODULATORS | |
| TW202227501A (zh) | 抗ｇａｒｐ抗體及其製造方法及用途 | |
| TW202545934A (zh) | 包含具有突變ｋｒａｓ蛋白分解誘導作用之雜環化合物的抗體藥物複合體 | |
| JP2022526831A (ja) | ヘテロ環式化合物およびその使用 | |
| EP4327823A1 (en) | Anti-cldn4/anti-cd137 bispecific antibody | |
| EP4245855A1 (en) | Anti-tspan8-anti-cd3 bispecific antibody and anti-tspan8 antibody | |
| JP2021516251A (ja) | 抗ｐｄ−１抗体との組み合わせのための抗ｃｄ１３７抗体 |